Semorinemab

Cat. No.: HY-P99399

CAS No.: 2159141-27-0

Target: Tau Protein

Pathway: Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a K_d value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease[1].

In Vitro

Semorinemab binds to human Tau and recombinant cynomolgus monkey Tau with K_d values of 3.8 and 11.2 nM, respectively[1].

Semorinemab prevents neurons to uptake oligomeric Tau[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Semorinemab (3, 10 and 30 mg/kg; i.p., once weekly for 13 weeks) reduces accumulation of Tau pathology in a transgenic (Tg) mouse model of tauopathy[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Tg mouse with the expression of human disease-causing tau mutant (TauP301L-Tg) [1]
Dosage:	3, 10 and 30 mg/kg
Administration:	Intraperitoneal injection; 3, 10 and 30 mg/kg, once weekly for 13 weeks
Result:	Reduced the accumulation of pathological tau, and dose-dependently decreased pTau212/214 and pTau202/205.

REFERENCES

[1]. Ayalon G, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA